Nurix Overview

  • Founded
  • 2009
Founded
  • Status
  • Public
  • Employees
  • 135
Employees
  • Stock Symbol
  • NRIX
Stock Symbol
  • Share Price
  • $28.35
  • (As of Thursday Closing)

Nurix General Information

Description

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Contact Information

Website
www.nurixtx.com
Formerly Known As
Kura Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 1700 Owens Street
  • Suite 205
  • San Francisco, CA 94158
  • United States
+1 (415) 000-0000

Nurix Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Nurix Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$28.35 $28.41 $21.53 - $52.38 $1.26B 44.6M 354K -$2.39

Nurix Financials Summary

In Thousands,
USD
TTM 31-Aug-2021 FY 2020 30-Nov-2020 FY 2019 30-Nov-2019 FY 2018 30-Nov-2018
EV 1,044,079 1,301,776
Revenue 29,043 17,820 31,115 37,449
EBITDA (97,264) (62,803) (19,882) (6,751)
Net Income (99,406) (43,242) (21,699) (9,428)
Total Assets 493,074 396,343 44,048 45,397
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Nurix Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Nurix‘s full profile, request access.

Request a free trial

Nurix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Nurix‘s full profile, request access.

Request a free trial

Nurix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of ora
Drug Discovery
San Francisco, CA
135 As of 2020
00000
00000000 00000

0000000

la pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt moll
0000 000000000
San Diego, CA
00 As of 0000
0000
0000 0000-00-00
00000000000 0000

00000 00

m dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
0000000000000
Lund, Sweden
000 As of 0000
00000
0.00 0000-00-00
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nurix Competitors (34)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cullgen Venture Capital-Backed San Diego, CA 00 0000 00000000000 0000
00000 000000000 Corporation Lund, Sweden 000 00000 000000000 00000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
000000 00000000000 Formerly VC-backed Watertown, MA 000 00000 00000000 00000
00 000000000000 Formerly VC-backed Durham, NC 000 00000 000000 - 000 00000
You’re viewing 5 of 34 competitors. Get the full list »

Nurix Patents

Nurix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210198280-A1 Bifunctional compounds for degrading btk via ubiquitin proteosome pathway Pending 04-Dec-2019 0000000000
US-20210087529-A1 Cbl inhibitors and compositions for use in adoptive cell therapy Pending 24-Sep-2019 000000000
US-20210085717-A1 Cbl inhibitors and compositions for expansion of immune cells Pending 24-Sep-2019 000000000
US-20210053961-A1 Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereof Pending 26-Jun-2019 0000000000
US-20210053986-A1 Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof Pending 17-May-2019 C07D403/12

Nurix Executive Team (15)

Name Title Board Seat Contact Info
Arthur Sands Ph.D Chief Executive Officer & Board Member
Hans van Houte Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Stefani Wolff Chief Operating Officer & Executive Vice President, Product Development
Gwenn Hansen Ph.D Chief Scientific Officer
Michael Lotze MD Chief Cellular Therapy Officer
You’re viewing 5 of 15 executive team members. Get the full list »

Nurix Board Members (13)

Name Representing Role Since
Arthur Sands Ph.D Nurix Chief Executive Officer & Board Member 000 0000
David Lacey MD Self Board Member 000 0000
Jeffrey Tong Ph.D Third Rock Ventures Board Member 000 0000
Judith Reinsdorf Self Board Member 000 0000
Julia Gregory Self Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Nurix Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nurix Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Nurix‘s full profile, request access.

Request a free trial